drugset / Trial / NCT05909293

Clinical Study Protocol of Maintenance Therapy With Venetoclax in Elderly Patients With AML in First Complete Remission

NCT05909293

NaSingle-groupOpen-labelTreatment

Summary

This clinical study evaluates the efficacy and safety of maintenance therapy with BCL-2 inhibitors in elderly patients with acute myeloid leukemia (AML) in first complete remission. This study involves the following content: BCL-2 inhibitors.

Timeline

Start
2023-04-12
Primary completion
2025-05-30
Completion
2028-05-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Venetoclax Small molecule 400 mg Oral